Pelthos Therapeutics Inc.

AMEX:PTHS

Biotechnology

Healthcare
$16.54 -1.28%

-$0.37 today

Market cap
$63.32M
Beta
3.13
P/E (TTM)
-0.7
EPS (TTM)
-$15.58
52W Low $16.50High $37.50

Volume 0.01M

Average 0.04M

PTHS Account Payables

Amounts the company owes suppliers for goods and services received.

Pelthos Therapeutics Inc.AMEX: PTHS

Account Payables · Q1 FY2026 · quarter ended Mar 2026

Account payables rises 136.1% from a year ago

Account payables stood at $6.15M at the end of Q1 FY2026, up 136.1% from a year earlier and up 105.9% from the prior quarter. Over 3 fiscal years it compounded at -0.1% a year.

Context

  • Account payables amounted to 4.2% of total assets at the end of Q1 FY2026, down 281.5 pp from a year earlier.
  • Account payables increased in 2 of the last 3 fiscal years.

What to watch

Whether account payables keeps rising in the next quarterly balance sheet after a +136.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.15M+105.9% QoQ
Last fiscal yearDec 2025
$2.99M+57.4% YoY
Year agoMar 2025
$2.6M+136.1% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+136.1%——
1 year+57.4%——
3-year CAGR-0.1%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
2.99M USD
Year-over-year change
+57.4%
3-year CAGR
-0.1%

Account Payables vs competitors

How PTHS compares with its peers on the latest reported figures

  • PTHS's Mar 2026 account payables of $6.15M is the highest of the 4 companies compared; the peer median is $2.67M.
  • Its year-over-year change of +136.1% is the lowest of 4, against a peer median of +247.7%.
  • Account payables amounts to 4.2% of total assets for PTHS, versus a peer median of 3.6%.
PTHS Competitors Peer median
Account Payables for PTHS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
PTHSPelthos Therapeutics Inc.Mar 2026$6.15M +136.1%-0.1%4.2%
ENLVEnlivex Therapeutics Ltd.Dec 2025$3.81M +369.5%+25.0%0.2%
CINGCingulate Inc.Mar 2026$2.67M +212.2%+38.7%8.7%
LIXTLixte Biotechnology Holdings, Inc.Mar 2026$391.08K +247.7%+1234.3%3.6%
Peer median (excluding PTHS) $2.67M+247.7%+38.7%3.6%

Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents55.07K96.39K513.44K18.02M
Short-term Investments0000
Net Receivables0040.4K8.86M
Inventory00023.57M
Other Current Assets00750K419K
Total Current Assets55.07K96.39K1.37M52.7M
Property, Plant & Equipment (Net)00012.84M
Goodwill00024.68M
Intangible Assets00039.47M
Long-term Investments0000
Tax Assets0000
Other Non-current Assets000711K
Total Non-current Assets00077.7M
Total Assets55.07K96.39K1.37M130.4M
Account Payables2.99M4.62M1.9M2.99M
Short-term Debt540.43K1.27M2.19M635K
Tax Payables0000
Deferred Revenue000966K
Other Current Liabilities221.88K645.95K021.41M
Total Current Liabilities3.76M6.54M4.08M25.99M
Long-term Debt00031.44M
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0001.28M
Other Non-current Liabilities00030.05M
Total Non-current Liabilities00065.52M
Total Liabilities3.76M6.54M4.08M91.52M
Common Stock1113916130
Retained Earnings(6.14M)(13.52M)(21.47M)(64.79M)
Accumulated OCI0000
Other Stockholders Equity0000
Minority Interest0000
Total Equity(3.71M)(6.44M)(2.71M)38.88M
Total Debt540.43K1.27M2.19M34.83M
Net Debt485.36K1.17M1.67M16.81M

Pelthos Therapeutics Inc.

AMEX:PTHS

Intrinsic Alpha fair value

Locked

Current Price

$16.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.